Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia



Summary

Pre-TCR-targeted immunotherapy aims to eliminate leukemic T cells in T cell acute lymphoblastic leukemia (T-ALL) by targeting the T cell receptor (TCR) before it fully assembles. This approach overcomes challenges associated with targeting mature TCRs, which can lead to T cell fratricide and antigen escape. Strategies include targeting TCR-associated proteins like CD3 or exploiting unique TCR rearrangements present in T-ALL cells. By targeting pre-TCR components or aberrant TCRs, these immunotherapies aim to selectively eliminate leukemic cells while sparing normal T cells, offering a potential for more effective and less toxic treatment for T-ALL.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!